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Background: The objective of our study was to determine if hepatic ultrasound findings in paediatric patients with cystic fibrosis and suspected
liver disease are related to histopathological results derived from liver biopsies.
Methods: A retrospective analysis of ultrasound and liver biopsy findings using published criteria was performed in 30 children with cystic
fibrosis suspected as having liver disease on clinical, biochemical and ultrasonographic criteria. The results were correlated and assessed for intra-
and interobserver agreement.
Results: A significant association was found for the prediction of fibrosis or cirrhosis on the basis of ultrasound (p=0.03). There was no significant
association between normal or indeterminate ultrasound and histology results. A high intra- and interobserver variability was found in sonographic
assessment of the hepatic echostructure.
Conclusions: The diagnosis of early liver disease in cystic fibrosis cannot reliably be made on the basis of ultrasound alone. A normal ultrasound
does not preclude significant liver fibrosis in cystic fibrosis. An abnormal US that suggests cirrhosis predicts the presence of moderate to severe
liver disease.
Crown Copyright © 2007 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. All rights reserved.Keywords: Cystic fibrosis; Ultrasound; Liver disease; Histology1. Introduction
The survival of patients with cystic fibrosis (CF) has
improved considerably over the past two decades as a result
of improved therapy. This has led to increased clinical relevance
of diseases in non respiratory systems [1].
Liver disease (LD) is a significant cause of mortality in the
CF population and was responsible for 5% of deaths before the
advent of liver transplantation [2]. Cirrhosis of the liver occurs
in up to 10% of the CF population and severe liver disease
typically occurs during the second decade of life [2–4]. Because
of the lack of specific and reliable non-invasive tests the⁎ Corresponding author. Tel.: +61 7 36367970; fax: +61 7 36361513.
E-mail address: kieran_frawley@health.qld.gov.au (K.J. Frawley).
1569-1993/$ - see front matter. Crown Copyright © 2007 Published by Elsevier B
doi:10.1016/j.jcf.2007.08.001prevalence of liver disease remains unknown with published
reports ranging up to a maximum of 72% at autopsy [5].
The exact pathophysiology of LD in CF is not yet fully
understood. The gene defect in CF encodes for the CF
transmembrane conductance regulator (CFTR). In the liver
CFTR is expressed only on the apical surface of the cells of the
biliary epithelium. The defect leads to malhydration of bile with
presumed obstruction of the intrahepatic biliary tree. Hepatic
stellate cells, the principal drivers of hepatic fibrosis are
activated and produce increased collagen with bile duct
epithelium demonstrated as the principal source of the
profibrogenic cytokine TGF-β [6]. This results in focal biliary
fibrosis characterized by inflammatory infiltrates, bile duct
proliferation and fibrosis [7–9]. Over several years this focal
fibrosis may progress to diffuse cirrhosis with regenerative
nodules and bridging fibrosis [8]. Hypotheses for the focal.V. on behalf of European Cystic Fibrosis Society. All rights reserved.
Table 1
Histologic grading after Scheuer [26]
Grade Fibrosis
0 None
1 Enlarged, fibrotic portal tracts
2 Periportal or portal–portal septa but intact architecture
3 Fibrosis with architectural distortion but no obvious cirrhosis
4 Probable or definite cirrhosis
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throughout the liver and partial compensation for the defect by
other mechanisms [8].
Despite the absence of agreed criteria for liver disease in CF
early diagnosis is recommended [3], which permits opportunity
for early intervention with ursodeoxycholic acid. It is thought
that ursodeoxycholic acid may improve the natural history of
CF related liver disease [10,11]. In the absence of reliable non-
invasive parameters, diagnosis of CFLD is currently made on
the basis of a combination of clinical, biochemical and US
findings with needle biopsy used in equivocal cases.
Ultrasound (US) is a widely employed modality for the
evaluation of liver diseases as it is readily available, non-
invasive and does not require sedation in younger children. It is
commonly used for the assessment of children with CF
suspected as having liver disease [2,12–15]. Computed
tomography has been used in correlation with US [16], but
the use of ionizing radiation is a major disadvantage particularly
with repeated screening in children and adolescents. MRI may
be a useful tool for assessment of LD although routine use of
MRI with CF has not yet been established [17]. In previous
studies US findings in patients with CF were correlated with
clinical and biochemical findings [13–15]. Limited data
however is available comparing sonographic findings with the
histology results of liver biopsy in patients with CF [2,10,14].
We wished to compare the findings on liver US with the
biopsy results in children with CF who fulfilled published
criteria for having liver disease [18] and to determine whether
specific US findings can be identified indicating CF related liver
disease (CFLD).
2. Material and methods
A retrospective analysis of ultrasound findings was per-
formed in 30 CF-patients (13 girls, 17 boys) who underwent a
liver biopsy and ultrasound between April 1997 and September
2003. The CF-patients undergoing liver biopsy were identified
from the cystic fibrosis clinic database. Ethical approval of this
study was granted by the institutional ethics committee as part
of a wide study into liver fibrosis in cystic fibrosis.
Patients' age ranged from 11 months to 17 years, mean age
10 years. The time interval between biopsy and ultrasound was
between 0 and 183 days (mean 42 days).
All patients were attending the CF clinic with positive sweat
tests confirming CF. Patients underwent liver biopsy if two out
of three of the following criteria were fulfilled: 1. evidence of
biochemical liver disease (persistent elevation of ALT above
upper limit of normal over a period of at least 6 months), 2.
clinical hepatomegaly or hepatosplenomegaly, 3. sonographic
evidence of liver disease. Informed consent was obtained from
the parents for the biopsy.
Percutaneous liver biopsy was performed using ultrasound
guidance. The ultrasound was used for biopsy guidance only
and a detailed ultrasound assessment of the liver was not per-
formed at the time of the biopsy. Two samples, to limit sampling
error, were obtained from the right lobe using a triggered trucut
to obtain 20 mm cores. No post biopsy complications wereobserved. In all specimens, at least 6 portal tracts were available
for analysis and a Scheuer grading for fibrosis was allocated to
each patient by a histopathologist blinded to US findings.
All sonograms were performed with one of the commercially
available real-time scanners: Acuson Sequoia (Siemens Ltd.
Medical, Erlangen, Germany) with 2.5–4 or 5.5–8.5 MHz-
probes or ATL HDI 5000 (Philips Medical Systems, Best, The
Netherlands) with 2–5 or 5–7 MHz-probes. US scans were
obtained after a 4-hour fast in children under 2 years and a 6-
hour fast in children over 2 years for gallbladder distension.
Sonographic images were independently reviewed two times
on hardcopies by a pediatric radiology fellow (investigator 1)
and an experienced paediatric radiologist (investigator 2). The
reviewers were unaware of the clinical findings and previous
interpretation and were blinded to the histology. After indepen-
dent review a consensus result was reached in cases with
differing interpretations for each of the ultrasound criteria
evaluated.
US and Doppler parameters that have been reported to be
associated with the presence of liver disease in CF were used
[12,16,19]. The whole liver was evaluated for echotexture and
contour. The echogenicity of the liver was compared with that of
the kidney (none of the patients had evidence of renal disease).
Hepatic echogenicity was considered abnormal if it was markedly
increased compared to the renal cortex and similar in echogenicity
to the renal sinus. Hepatic parenchyma was assessed as
inhomogeneous if variable echogenicity and loss of definition
of portal tracts was noted. Presence or absence of nodularity at the
hepatic contour was assessed. Periportal echogenicity was called
abnormal if its maximum diameter extended over 2 mm [16].
Attenuation was assessed as abnormal if a clear image of the right
liver and kidneywas obtained, but blurring of deep structures was
noted with imaging of the liver alone. The diameter of the portal
vein was regarded as normal within these limits: 8.5+ /
−2.7 mmb10 years, 10+/−2 mmN10 years [20]. Normal portal
vein mean flow velocity was assessed as greater than 15 cm/s
[21].
The gallbladder was assessed as abnormal in size if the
length was below 2 cm after fasting [22]. A wall thickness
greater than 3 mm was considered abnormal [23]. Presence or
absence of gallstones was noted. The diameter of the common
bile duct was assessed and considered as normal if smaller than
4 mm [23]. Spleen size was regarded normal if the spleen did
not extend over the inferior margin of the left kidney [24].
Measurements of the splenic length were performed and
correlated with normal values from the literature [25]. Presence
or absence of varices and ascites was noted.
Fig. 1. Summary of the ultrasound and histology results.
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each reviewer. There were three categories: normal, indetermi-
nate (suggestion of liver disease but no definite signs of
cirrhosis) and cirrhosis.
Cases without liver abnormality were graded as normal.
Increased hepatic echogenicity, heterogeneity and/or increased
attenuation in the absence of nodularity of the liver surface were
classified as indeterminate. Splenomegaly as an isolated finding
was also regarded as indeterminate. All patients with nodularity
of the liver surface were classified as cirrhosis.Table 2
Patients' details with clinical grading, individual Scheuer Scores, summary US inter
Sex Age (years) ALT (U/l) PHT Scheuer
1 F 5 110 No 0
2 M 6 58 No 0
3 M 2 60 No 0
4 F 8 44 No 0
5 M 17 82 No 0
6 F 15 35 No 0
7 M 10 35 No 0
8 M 9 35 No 1
9 F 2 41 No 1
10 M 6 50 No 1
11 F 16 64 No 1
12 F 14 50 No 1
13 F 11 65 No 1
14 M 11 41 No 2
15 F 10 17 No 2
16 F 12 40 No 2
17 M 15 35 No 2
18 M 15 146 Yes 2
19 M 12 50 Yes 2
20 F 11 15 No 3
21 M 10 84 Yes 3
22 M 8 50 Yes 3
23 F 5 60 Yes 3
24 F 14 132 Yes 3
25 M 3 35 No 3
26 M 17 35 Yes 4
27 M 4 100 Yes 4
28 F 15 86 Yes 4
29 M 10 36 Yes 4
30 F 11 20 Yes 4
ALT = Alanine aminotransferase. PHT = Clinical portal hypertension with splen
Heterogeneity. Nodular =Nodularity. GB abn = Abnormality of gallbladder. Spleen2.1. Histological scoring system
The scoring system of Scheuer was used for histological
grading [26] (see Table 1).
Scheuer-Score of 0 was regarded as normal, a score of 1–2 as
mild to moderate reversible periportal changes and 3–4 was
assessed as definite fibrosis/cirrhosis.
2.2. Statistical analysis
The association between US findings and histology results
was evaluated using the chi-square test, or Fisher's exact test if
cell frequencies were b5. Sensitivity and specificity of US for
the diagnosis of ‘normal’ liver and for the diagnosis of ‘fibrosis/
cirrhosis’ were calculated as the proportion of those with the
condition of interest who were classified as positive on US, and
the proportion of those without the condition of interest who
were classified as negative on US, respectively, and reported
with 95% confidence intervals. The Mantel–Haenzel chi-square
test for trend was used to evaluate the association between
frequency of diagnosis of cirrhosis on US and increasing
Scheuer score. Ninety-five percent confidence intervals are
given for test characteristics where appropriate. Intra- and
interobserver agreement was estimated on the above criteria and
US summary interpretation using the kappa statistics, where apretation and selected US finding
US Echo Hetero Nodular GB abn Spleen
N Yes
N
N Yes
N Yes
I Yes
I Yes Yes
C Yes Yes Yes Yes
N
N Yes
N
I Yes
I Yes Yes
I Yes
N
N
N
I Yes Yes Yes
C Yes Yes Yes
C Yes Yes Yes
N
N
I Yes Yes
C Yes Yes Yes Yes Yes
C Yes Yes Yes Yes
C Yes Yes
I Yes
I Yes
C Yes Yes Yes
C Yes Yes Yes
C Yes Yes Yes Yes
omegaly or varices at endoscopy. Echo = Increased echogenicity. Hetero =
= Splenomegaly. US findings: N = Normal, I = Indeterminate, C = Cirrhosis.
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value of 1 indicates perfect agreement. Data analysis was
performed using SAS software (version 9.1, SAS Institute Inc,
Cary, North Carolina).
3. Results
Out of our study group of 30 patients referred for evaluation
of suspected liver disease, US was interpreted as normal in 12
cases. Of these 12 with normal US, four patients had normal
histology six had mild to moderate fibrosis (Scheuer-Score 1 or
2) and two had advanced fibrosis (Scheuer Grade 3). A sum-
mary of the ultrasound and histology results is given in Fig. 1.
No significant association between normal US and histology
classified as ‘normal’ (Scheuer-Score 0) was found (χ2 =1.12,
p=0.29). The sensitivity of US to detect normal histology in our
data was 0.57 (0.18–0.90) with a specificity of 0.65 (0.52–
0.91). Corresponding positive predictive value was 0.33 (0.10–
0.65) and negative predictive value 0.83 (0.58–0.96).
In nine patients US-results were indeterminate. Mild
periportal changes on histology were noted in four of these
patients and in two cases normal histology was found. In three
patients, fibrosis or cirrhosis was found on histology, this
included one patient with splenomegaly as the only pathologicFig. 2. Representative sonographic findings (findings on histology in parentheses):
inhomogeneous liver (mild periportal changes), c. distinct inhomogeneity of liver stfinding at US who had cirrhosis on histology. No statistical
significant relationship was found between indeterminate US
and the histology results.
In nine patients US was interpreted as cirrhosis on the basis
of nodularity of the liver surface. All nine patients demonstrated
heterogeneity of the liver parenchyma and splenomegaly was
found in all but one patient. Six of these were found to have
advanced fibrosis on histology. Two had only moderate fibrosis
(Scheuer Grade 2) and one patient had no fibrosis on biopsy.
During follow up, both patients with only moderate fibrosis
progressed to portal hypertension (PHT) with splenomegaly and
both developed advanced fibrosis on repeat biopsy 2 years later.
The patient with no fibrosis on biopsy demonstrated moderate
fibrosis (Scheuer Grade 2) on biopsy 3 years later and a follow
up ultrasound performed 4 months prior to the second biopsy
(investigator 2) showed a heterogeneous nodular liver and
splenomegaly in this patient.
There was a significant association between a summary
finding of cirrhosis on the basis of US and liver histology
(p=0.04, Fisher's exact test). The sensitivity to detect fibrosis or
cirrhosis with US was 0.55 (0.23–0.83) with a specificity of
0.84 (0.60–0.97). Corresponding positive predictive value was
0.67 (0.29–0.92) and negative predictive value 0.76 (0.52–
0.92). There was also a significant association between cirrhosisa. normal appearing liver (moderate periportal changes), b. echogenic, slightly
ructure (fibrosis), d. nodular liver surface (cirrhosis).
Table 3
Intra- and interobserver agreement for selected US-criteria (kappa)
Intraobserver agreement Interobserver agreement
Investigator 1 Investigator 2 1st reading 2nd reading
Echogenicity 0.39 0.56 0.44 0.53
Inhomogeneity 0.45 0.63 0.45 0.45
Nodularity 0.76 0.76 0.62 0.65
Attenuation 0.79 0.72 0.55 0.50
Spleen size 0.60 0.94 0.69 0.95
Normal 0.70 0.79 0.56 0.51
Indeterminate 0.39 0.70 0.26 0.29
Cirrhosis 0.45 0.94 0.67 0.54
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( p=0.04, Fisher's exact test) and splenomegaly ( p=0.05,
Fisher's exact test).
A significant associationwas found between theUS finding of a
microgallbladder and non-fibrotic liver (p=0.006). In 24 patients
where the gallbladder was visualised, all of the five patients with
normal histology had amicrogallbladder,whereas of the 19 patients
with abnormal histology, only five had a microgallbladder and the
remaining 14 had a ‘normal’ sized gall bladder.
Patient details including the clinical grading, individual
Scheuer Scores, selected US findings and summary US
interpretation are listed in Table 2.
Representative US findings are depicted in Fig. 2.
3.1. US findings: Inter-/intraobserver agreement
Highest kappa values for intraobserver agreement (0.76–0.94)
were obtained for nodularity, attenuation and spleen size.
Interobserver agreement demonstrated highest kappa values
(0.62–0.95) for nodularity and spleen size.
It is noted that kappa values for hepatic homogeneity/
coarseness were relatively low, indicating high variance in
interpretation. Selected kappa values are shown in Table 3.
No abnormal findings were demonstrated in our series for the
following US-criteria: periportal echogenicity, portal vein
diameter and flow velocity, gallbladder wall thickness, gall-
stones, diameter of the common bile duct, varices and ascites.
These were therefore excluded from further analysis.
4. Discussion
We have demonstrated that the exclusion of early CF related
liver disease is not reliably made with US. Specifically we have
demonstrated the positive predictive value of a normal
ultrasound is only 33% and a sensitivity of 57%. A significantly
abnormal US however is a good predictor of advanced liver
disease with a specificity of at least 84%, as there may be some
variability with the liver biopsy. The specific findings of
nodularity and splenomegaly seem to be reliable markers of
advanced fibrosis.
Due to its low cost, US is the ideal tool for imaging these
patients with CF, but awareness of the limitations of each modality
in specific disorders is crucial for good clinical management.The strongest association of hepatic US-criteria to histology
results was obtained for nodularity of the liver surface. A
statistically significant association was demonstrated between
hepatic nodularity and fibrosis/cirrhosis. These findings are in
keeping with results from previous studies relating US findings
to liver function using biochemical and clinical parameters
[12,27].
As with other forms of cirrhotic liver disease, splenomegaly
appears to be a reliable indicator of liver cirrhosis and portal
hypertension, confirmed in our series where splenomegaly was
associated with hepatic fibrosis or cirrhosis. Other previously
described indicators of PHT (collateral vessels, lesser omental
thickening) [15] were not identified in our series.
Hepatic parenchymal inhomogeneity has been observed in
several studies and is assumed to reflect liver disease, however
without histopathologic confirmation of these findings [12,27].
In our series hepatic inhomogeneity was not a reliable criterion
in comparison with histology. Inhomogeneity was observed in
patients with and without histopathologic evidence of LD.
The prevalence of a microgallbladder is reported as 30% in
all CF-patients [4] and this is in keeping with our results.
Interestingly the association between normal gallbladder size
and liver disease is statistically significant in our series. With the
small number in our series however further investigation of this
finding appears necessary.
US may be more sensitive for CFLD than clinical and
biochemical abnormalities [15]. This conclusion is supported by
the results of our series, where initial US findings detected
pathological changes before histologic fibrosis was demon-
strated. On the other hand, it has been shown that patients with
normal US can have severe hepatic fibrosis [2,10] and that
biochemical abnormalities can occur before sonographic
changes are detected [28].
Our results are similar to the findings of Lindblad et al. who
examined 41 patients with CF including adults. In their group
with normal US, two out of 21 patients were found to have
moderate to severe fibrosis [2]. The series reported by Spray et
al. [10] consisted of 18 US/histology pairs. In their series three
out of four patients with normal US demonstrated cholangitis,
portal fibrosis or steatosis in histology.
The role of liver biopsy for diagnosing liver disease in CF
has been controversial in light of sampling tissue from a focal
disease [29,30]. These concerns are not confined to CF, but
broadly apply to liver diseases particularly those involving
biliary disorders such as sclerosing cholangitis.
At present, liver biopsy remains the only test for assessing
fibrosis even with these acknowledged concerns of sampling
reliability [2]. Support for biopsy is also given by other authors
[29,30] who demonstrated similar morphology over time with
repeated needle biopsies. Potter et al. [31] performed open
wedge biopsies with simultaneous needle biopsy in five
patients and found similar histology. Our observations suggest
that liver biopsy can miss advanced fibrosis, as demonstrated
by the patient with US findings of cirrhosis with a normal
biopsy. A subsequent repeat biopsy 3 years later showed
fibrosis. The ultrasound was consistently abnormal during this
period.
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agreement in evaluating the echostructure of the liver. This is in
keeping with the observation by Dietrich et al. [32], who found
the interpretation of hepatic inhomogeneity to be largely
subjective.
Williams et al. [13] in contrast found a high level of
agreement in their study. This may partly be explained by less
variation in image characteristics with US performed by a single
observer. But even in this ideal setting the assessment of mild
hepatic structural changes in our experience leads to varying
results.
A limitation of this study is the small number of patients.
Nevertheless, this is the largest cohort of CF-patients with
comparison of liver histology and specific sonographic findings
investigated to date. Another potential limitation of this study
was that the ultrasound accuracy was measured against liver
biopsy but liver biopsy itself may result in sampling errors [2].
At present, there is no gold standard for the diagnosis of cystic
fibrosis liver disease but liver biopsy, with its recognised
sampling limitations, remains the standard for assessing liver
fibrosis [2]. As this is a retrospective study, US examinations
and liver biopsies were not timed and a prolonged time interval
could lead to discrepancies in observation. However there is
evidence that CFLD is a slowly progressing disease [2] and a
significant impact on the results therefore appears to be unlikely.
The recently described high resolution sonography of the liver
surface [33] was not part of our imaging protocol, however the
focal character of CFLD may limit benefits of this technique in
our patient population.
In summary our findings demonstrate that the diagnosis of
early liver fibrosis cannot reliably be made on the basis of US
alone. A normal US does not preclude liver fibrosis in patients
with CF and may still require biopsy [2].
An abnormal US that suggests cirrhosis however does
predict the presence of moderate to severe LD and liver biopsy
in these patients may potentially be avoided. Hepatic nodularity
and splenomegaly are good predictors of cirrhosis.
Identifying early LD in CF remains a challenging task and
further research is required to define the individual value of
clinical, biochemical and imaging findings.
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